The World Health Organization published a meeting report from its paediatric drug optimisation exercise for dengue, identifying treatment priorities for children, according to global health reporting. Dengue fever affects millions annually in tropical regions, with severe forms posing mortality risk especially among younger patients.
Paediatric drug optimisation reviews existing medicines and formulations to align dosing, safety and access for children. WHO-led exercises convene experts to rank research needs when evidence for child-specific regimens is limited.
Dengue vaccines and vector control supplement clinical care but do not eliminate treatment gaps during outbreaks. The summary did not list specific drugs prioritized or trial timelines proposed.
Manufacturers and regulators use WHO guidance to plan pediatric studies and label expansions. Monsoon seasons in South Asia often bring surges requiring hospital preparedness.
Member states may integrate findings into national dengue management protocols.
WHO published a paediatric drug optimisation report on dengue after an expert exercise that set treatment priorities for children. The meeting output is intended to guide research and access for young patients, without named drug candidates in the summary.
Paediatric dengue treatment gaps guided the priorities listed in WHO’s optimisation meeting report.
Dengue burden in children remains a focus for WHO-led drug access and formulation work.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.who.int/news